Activation of antigen-exposed iMC-DCs at the “right place” and “right time” promotes potent anti-tumor immunity

To better control the “licensing” of pro-Th1 dendritic cells (DCs), Spencer and colleagues have developed a synthetic ligand-inducible chimeric receptor, iMyD88/CD40 (iMC), incorporating synergistic Toll-like receptor (TLR) and costimulatory signaling elements, permitting DC regulation in vivo withi...

Descripción completa

Detalles Bibliográficos
Autor principal: Spencer, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382847/
https://www.ncbi.nlm.nih.gov/pubmed/22737615
http://dx.doi.org/10.4161/onci.18482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382847/
https://www.ncbi.nlm.nih.gov/pubmed/22737615
http://dx.doi.org/10.4161/onci.18482

Ejemplares similares